Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock

Chimerix, Inc. (NASDAQ:CMRX) insider Allen S. Melemed sold 3,065 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.50, for a total value of $13,792.50. Following the transaction, the insider now owns 152,875 shares of the company’s stock, valued at $687,937.50. This represents a 1.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Chimerix Stock Performance

Shares of CMRX stock opened at $4.38 on Friday. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $4.65. The firm has a market capitalization of $393.94 million, a PE ratio of -4.66 and a beta of 0.35. The stock has a fifty day moving average of $3.53 and a two-hundred day moving average of $1.82.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently bought and sold shares of the stock. Boxer Capital Management LLC bought a new stake in shares of Chimerix during the 4th quarter worth about $7,169,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the fourth quarter valued at approximately $62,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the fourth quarter valued at approximately $59,000. Diadema Partners LP acquired a new position in shares of Chimerix during the fourth quarter valued at approximately $101,000. Finally, Marshall Wace LLP raised its holdings in Chimerix by 1,318.5% during the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after purchasing an additional 2,057,864 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.